Citigroup
ELDN icon

Citigroup’s Eledon Pharmaceuticals ELDN Stock Holding History

Citigroup’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.8K Buy
3,498
+2,219
+173% +$5.23K ﹤0.01% 5005
2025
Q4 		$1.93K Buy
1,279
+469
+58% +$1.11K ﹤0.01% 5461
2025
Q3 		$2.1K Sell
810
-18,928
-96% -$55.3K ﹤0.01% 5470
2025
Q2 		$53.5K Sell
19,738
-1,273
-6% -$3.82K ﹤0.01% 4719
2025
Q1 		$71.2K Sell
21,011
-45,889
-69% -$189K ﹤0.01% 4769
2024
Q4 		$276K Buy
+66,900
New +$264K ﹤0.01% 4200
2021
Q2 		– Sell
-2,166
Closed -$23K – 6183
2021
Q1 		$23K Buy
+2,166
New +$32.7K ﹤0.01% 5163
2017
Q2 		– Sell
-1
Closed – – 7367
2017
Q1 		$0 Sell
1
-61
-98% -$8.96K ﹤0.01% 7211
2016
Q4 		$10K Buy
62
+29
+88% +$5.56K ﹤0.01% 6741
2016
Q3 		$8K Hold
33
– – ﹤0.01% 6620
2016
Q2 		$30K Sell
33
-68
-67% -$75K ﹤0.01% 5890
2016
Q1 		$92K Buy
101
+23
+29% +$22.6K ﹤0.01% 5720
2015
Q4 		$111K Buy
78
+36
+86% +$62.7K ﹤0.01% 5296
2015
Q3 		$71K Buy
42
+11
+35% +$22.7K ﹤0.01% 5204
2015
Q2 		$67K Sell
31
-5
-14% -$9.67K ﹤0.01% 5303
2015
Q1 		$67K Buy
36
+30
+500% +$66.2K ﹤0.01% 5321
2014
Q4 		$15K Buy
6
+2
+50% +$4.75K ﹤0.01% 6333
2014
Q3 		$11K Buy
+4
New +$11.4K ﹤0.01% 6213

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Citigroup's ELDN Position: Q1 2026 in Review

Citigroup increased its Eledon Pharmaceuticals (ELDN) stake by 173% in Q1 2026, buying an estimated $5.23K and bringing the position to 3,498 shares worth $10.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5005.

Citigroup first reported a position in ELDN in Q3 2014 and has held it in 18 quarters since. The position peaked at $276K in Q4 2024. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Citigroup held 3,498 shares of Eledon Pharmaceuticals worth $10.8K as of Q1 2026.
  • Citigroup bought 2,219 Eledon Pharmaceuticals shares in Q1 2026, an estimated $5.23K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5005 holding.
  • Citigroup first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 18 quarters since.
  • Citigroup's Eledon Pharmaceuticals position peaked at $276K in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.